We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




X-ray Crystallography Reveals Cell's Fight Against Cancer

By Biotechdaily staff writers
Posted on 22 Sep 2006
By the precise use of x-ray crystallography to monitor motion in very large molecules, researchers have captured a first look at the life-or-death struggle of a cancer-causing protein--LTag--and a major tumor-suppressor--p53. More...


Each lethal LTag (large T antigen) by itself ties up a group of six p53 molecules, inhibiting their tumor-suppressant role, the researchers reported in their study, which was published in the September 1, 2006, issue of the journal Genes & Development. Undaunted, the p53 molecules fight back by preventing replication of the virus that produces LTag, known as an oncoprotein because of its role in cancer growth. The winner of the battle depends on which side is healthier and stronger.

"If you have a lot of functional p53, you can override large T antigens,” said lead researcher Dr. Xiaojiang Chen, professor in molecular and computational biology at the University of Southern California (USC; Los Angeles, CA, USA) College of Letters, Arts, and Sciences.

Sometimes called the "guardian of the genome,” an injured p53 can leave a cell nearly defenseless. "p53 is a very important tumor suppressor that's mutated in a vast majority of all cancers,” stated Dr. James Pipas, professor of biologic sciences at the University of Pittsburgh (PA, USA).

Dr. Pipas, after studying LTag for many years, was astounded at its varied biologic functions--including very efficient tumor promotion—and named it the most amazing molecule in the universe in one of his presentations. Dr. Pipas called Dr. Chen's new study "a very important piece of work” that demonstrates how a healthy cell's tumor defenses break down. "Understanding exactly how this works is going to be a critical step toward our understanding of tumor genesis,” he said.

This, in turn, may lead to new methods for devising tumor-fighting drugs, Dr. Pipas added. Dr. Chen's team was able to describe the interaction between LTag and p53 by crystallizing the complex of one LTag and six p53 molecules, totaling more than 50,000 atoms between them. "It's quite a technical achievement, because these are fairly large proteins,” Dr. Pipas said.

Dr. Chen reported that his study gave him new respect for LTag and its parent, simian virus 40 (SV40). SV40 has long been used as a research tool to induce cancers in cell cultures. "Somehow this virus knows how important p53 is, and has this oncoprotein [Ltag] to target it by physically interacting with it and changing its conformation,” Dr. Chen said. If the virus succeeds, the outcome is a new tumor.



Related Links:
University of Southern California

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Pipette Calibration System
Artel PCS®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.